These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36615779)

  • 1. Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a.
    Wang Z; Zhu Y; Xia L; Li J; Song M; Yang C
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
    Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
    Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
    Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
    Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficiency of ADAR2 ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in obese mice.
    Kung ML; Cheng SM; Wang YH; Cheng KP; Li YL; Hsiao YT; Tan BC; Chen YW
    Commun Biol; 2024 May; 7(1):594. PubMed ID: 38760406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.
    Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W
    J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p.
    Zhang B; Li H; Li D; Sun H; Li M; Hu H
    Gene; 2019 Jun; 700():139-148. PubMed ID: 30898698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAR2 deficiency ameliorates non-alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.
    Kung ML; Yang TH; Lin CC; Ho JY; Hung TC; Chang CH; Huang KW; Chen CC; Chen YW
    J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):949-962. PubMed ID: 38533529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
    Shan W; Gao L; Zeng W; Hu Y; Wang G; Li M; Zhou J; Ma X; Tian X; Yao J
    Cell Death Dis; 2015 Jul; 6(7):e1833. PubMed ID: 26203862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-218-5p promotes hepatic lipogenesis through targeting Elovl5 in non-alcoholic fatty liver disease.
    Wu G; Zhang Y; Liang B; Yin L; Gao M; Zhang H; Xu Y; Han X; Qi Y; Liu F; Xu L
    Biochem Pharmacol; 2024 Aug; 226():116411. PubMed ID: 38972428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of miR-34a in regulating steatosis by targeting PPARĪ± expression in nonalcoholic fatty liver disease.
    Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
    Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerobic endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 dependent autophagy induction in high fat diet fed mice.
    Ghareghani P; Shanaki M; Ahmadi S; Khoshdel AR; Rezvan N; Meshkani R; Delfan M; Gorgani-Firuzjaee S
    Obes Res Clin Pract; 2018; 12(Suppl 2):80-89. PubMed ID: 28163011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206.
    Chen X; Tan QQ; Tan XR; Li SJ; Zhang XX
    Cell Death Dis; 2021 Aug; 12(9):809. PubMed ID: 34446693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-32-5p induces hepatic steatosis and hyperlipidemia by triggering de novo lipogenesis.
    Wang YD; Wu LL; Mai YN; Wang K; Tang Y; Wang QY; Li JY; Jiang LY; Liao ZZ; Hu C; Wang YY; Liu JJ; Liu JH; Xiao XH
    Metabolism; 2023 Sep; 146():155660. PubMed ID: 37451670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.
    Zhang ZC; Liu Y; Xiao LL; Li SF; Jiang JH; Zhao Y; Qian SW; Tang QQ; Li X
    J Hepatol; 2015 Dec; 63(6):1466-75. PubMed ID: 26272872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
    Hong Y; Choi SI; Hong E; Kim GH
    J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
    Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G
    J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
    Zhang M; Tang Y; Tang E; Lu W
    Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis.
    BinMowyna MN; AlFaris NA; Al-Sanea EA; AlTamimi JZ; Aldayel TS
    Arch Physiol Biochem; 2024 Jun; 130(3):300-315. PubMed ID: 35254877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
    Chen L; Wu N; Kennedy L; Francis H; Ceci L; Zhou T; Samala N; Kyritsi K; Wu C; Sybenga A; Ekser B; Dar W; Atkins C; Meadows V; Glaser S; Alpini G
    Hepatology; 2021 Oct; 74(4):1845-1863. PubMed ID: 33928675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.